Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
Phase 3positiveIvonescimabPembrolizumabPositive
AI Analysis
Summary
Akeso announced that ivonescimab met the key secondary endpoint of overall survival in an interim analysis of the Phase III HARMONi-2 trial, showing statistically significant and clinically meaningful benefit versus pembrolizumab in first-line PD-L1-positive NSCLC.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Ivonescimab met key secondary endpoint of overall survival in interim analysis of HARMONi-2 (AK112-303) trial, demonstrating statistically significant and clinically meaningful benefit versus pembrolizumab in first-line PD-L1-positive NSCLC
Importance:8/10
Sentiment:
0.80
oncologyNSCLCimmunotherapyinterim analysisoverall survival
Related Companies
Read the original article
Published by PR Newswire Pharma on September 2, 2026 9:00 PM